First Approval Bodes Well For Hanmi’s Olmutinib
This article was originally published in PharmAsia News
Hanmi’s novel lung cancer drug olmutinib is set to debut on the South Korean market later this year following its first approval globally after a fast-track review. The therapy will gain a domestic head start over AstraZeneca’s Tagrisso and international licensing deals have already been reached with Boehringer Ingelheim and ZAI Lab.
Register for our free email digests: